In AML, constitutive STAT5 signaling is observed in the majority of cases, resulting from either mutations in upstream receptor tyrosine kinases such as FLT3 and c-KIT, or autocrine growth factor production [17]–[20]. This evidence concerns the gene STAT5B and acute myeloid leukemia.